- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.11.25 | Novartis' Itvisma gets FDA approval for spinal muscular atrophy treatment | ||
| 28.11.25 | Regeneron's Libtayo receives EC approval for skin cancer | ||
| 28.11.25 | ESMO 2025 - ensuring innovation isn't lost in translation | ||
| 27.11.25 | Sandoz launches first and only multiple sclerosis biosimilar in US | ||
| 27.11.25 | Tonix launches new oral fibromyalgia treatment | ||
| 27.11.25 | Agility in medical affairs: responding to rapid market and regulatory shifts | ||
| 27.11.25 | Optimised therapy to improve outcomes for heart attack and stroke patients | ||
| 27.11.25 | The new era of medical affairs: busting myths and supercharging strategic value | ||
| 26.11.25 | J&J's Tremfya improves symptoms of psoriatic arthritis including joint damage | ||
| 26.11.25 | Novartis announces plans for new US manufacturing hub | ||
| 25.11.25 | The most overlooked KPI in business? Joy | ||
| 25.11.25 | Reimagining pharma CX: three game-changing products driving human-centric innovation | ||
| 25.11.25 | When populism meets public health: trust under siege | ||
| 25.11.25 | The building of Aspire Pharma and values | ||
| 25.11.25 | Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug | ||
| 25.11.25 | Major prostate cancer screening trial launched in UK | ||
| 24.11.25 | Pfizer's PADCEV gets FDA approval for bladder cancer | ||
| 24.11.25 | AstraZeneca announces $2bn investment in US manufacturing | ||
| 21.11.25 | Novartis reports primary endpoint reached in phase 3 malaria trial | ||
| 21.11.25 | Merck agrees deal with Cidara Therapeutics worth almost $9.2bn | ||
| 20.11.25 | PMEA 2025: a celebration of excellence in pharmaceutical marketing | ||
| 20.11.25 | J&J receives positive NICE recommendation for multiple myeloma treatment | ||
| 20.11.25 | VML Portugal appoints Managing Director | ||
| 20.11.25 | Younger, not invisible: rewriting cancer care - starting with the pancreas | ||
| 19.11.25 | Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer's treatment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .